On April 30th of this year, the FDA approved Kloxxado, a naloxone nasal spray that contains 8mg of naloxone per dose, which is twice as much as the most common formulation: Narcan. But what distinguishes Kloxxado distinguishes from the many other ways that naloxone is delivered and why was it developed in the first place?
Published On: 8/16/2021
Duration: 21 minutes, 01 seconds
Articles Referenced: "A New High-Dose Naloxone: Life Saver or Punishment?," The Carlat Addiction Treatment Report," July/August 2021;
"Naloxone Prescribing," The Carlat Addiction Treatment Report," July/August 2021
Got feedback? Take the podcast survey.